Prophylactic anticoagulation aids hospitalized COVID-19 patients

Prophylactic anticoagulation aids hospitalized COVID-19 patients

(HealthDay)—Prophylactic-dose venous thromboembolism (VTE) anticoagulation may be optimal therapy for patients hospitalized with COVID-19, according to a study published online June 11 in JAMA Network Open.

Valerie M. Vaughn, M.D., from the University of Utah in Salt Lake City, and colleagues assessed trends in VTE prophylaxis and treatment-dose in patients hospitalized for COVID-19, as well as the association of anticoagulation strategies with in-hospital and 60-day . The analysis included a pseudorandom sample of 1,351 patients hospitalized between March 7, 2020, and June 17, 2020, in 30 hospitals in Michigan.

The researchers found that 1.3 percent had a confirmed VTE, while 16.2 percent received treatment-dose anticoagulation. Across hospitals, 0 to 29 percent used treatment-dose anticoagulation without imaging, with increases over time (adjusted odds ratio [aOR], 1.46 per week; 95 percent confidence interval [CI], 1.31 to 1.61). Among the 1,127 patients who ever received anticoagulation, more than one-third (34.8 percent) missed two or more days of prophylaxis (range from 11 to 61 percent across hospitals), with a decrease in missed prophylaxis seen over time (aOR, 0.89 per week; 95 percent CI, 0.82 to 0.97). An association was seen between nonadherence to VTE prophylaxis and higher 60-day mortality (adjusted hazard ratio [aHR], 1.31; 95 percent CI, 1.03 to 1.67) but not in-hospital mortality (aHR, 0.97; 95 percent CI, 0.91 to 1.03). The investigators observed an association between receiving any dose of anticoagulation and lower in-hospital mortality (only prophylactic dose: aHR, 0.36 [95 percent CI, 0.26 to 0.52]; any treatment dose: aHR, 0.38 [95 percent CI, 0.25 to 0.58]), but only the prophylactic dose of anticoagulation remained associated with lower mortality at 60 days (prophylactic dose: aHR, 0.71 [95 percent CI, 0.51 to 0.90]; treatment dose: aHR, 0.92 [95 percent CI, 0.63 to 1.35]).

"Given that only prophylactic anticoagulation was associated with lower 60-day mortality, prophylactic-dose VTE prophylaxis may be the optimal therapy for hospitalized with COVID-19," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further

Early anticoagulation may not up survival in severe COVID-19

More information: Abstract/Full Text
Journal information: JAMA Network Open

Copyright © 2021 HealthDay. All rights reserved.

Citation: Prophylactic anticoagulation aids hospitalized COVID-19 patients (2021, June 23) retrieved 24 October 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors